Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors-Reference-Cited by-同舟云学术

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors

Published:2018-02-21 Issue:4 Volume:81 Page:727-737
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Marmé Frederik,Gomez-Roca Carlos,Graudenz Kristina,Huang Funan,Lettieri John,Peña Carol,Trnkova Zuzana Jirakova,Eucker Jan

Funder

Bayer HealthCare Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3540-9/fulltext.html

Reference26 articles.

1. Wilhelm SM et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

2. Nexavar (sorafenib) prescribing information, Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, 2015

3. Carlomagno F et al (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326–334

4. Maemura M, Iino Y, Koibuchi Y, Yokoe T, Morishita Y (1999) Mitogen-activated protein kinase cascade in breast cancer. Oncology 57:37–44

5. Dybdal-Hargreaves NF, Risinger AL, Mooberry SL (2015) Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res 21:2445–2452

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Influence of Paracetamol on the Penetration of Sorafenib and Sorafenib N-Oxide Through the Blood–Brain Barrier in Rats;European Journal of Drug Metabolism and Pharmacokinetics;2020-08-10

2. In vivo assessment of the drug interaction between sorafenib and paracetamol in rats;Cancer Chemotherapy and Pharmacology;2020-05-11